Safety and tolerability of the implantable recurrent laryngeal nerve stimulator.
The recurrent laryngeal nerve (RLN) stimulator has been implanted on a limited basis since 1988 for control of spasmodic dysphonia. A similar vagus nerve stimulator has been implanted in a larger series of patients to control epilepsy. The safety and tolerability of these two stimulators were evaluated. In 113 patients implanted with the vagus nerve stimulator, the complication rate was 0.9%. All patients were monitored for vital signs, electrocardiographic changes, and adverse effects. The absence of changes in vital signs and electrocardiograms during vagal stimulation establishes the safety of this treatment. Since placement of the electrode around the vagus nerve is an easier surgical technique than placement deep to the RLN, it seems reasonable to change the technique to implant the stimulator on the vagus in patients with spasmodic dysphonia.
Friedman
M
M
Department of Otolaryngology and Bronchoesophagology, Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612.
Wernicke
J F
JF
Caldarelli
D D
DD
D004599:Electric Stimulation Therapy / Q000009:adverse effects; D004562:Electrocardiography; D015716:Electrocardiography, Ambulatory; D004567:Electrodes, Implanted; D004827:Epilepsy / Q000628:therapy; D006339:Heart Rate; D006801:Humans; D012009:Recurrent Laryngeal Nerve / Q000502:physiology*; D012449:Safety; D014630:Vagus Nerve / Q000502:physiology; D014832:Voice Disorders / Q000628:therapy*